NCT02205372View on ClinicalTrials.gov

Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

July 31, 2014

Primary Completion Date

August 31, 2015

Study Completion Date

August 31, 2015

Conditions
Diabetic Nephropathy
Interventions
DRUG

MT-3995

DRUG

Placebo

Trial Locations (1)

Unknown

Touei Hospital, Sapporo

Sponsors
All Listed Sponsors
lead

Mitsubishi Tanabe Pharma Corporation

INDUSTRY